| Project/Area Number |
24580460
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical veterinary science
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
OKUDA Masaru 山口大学, 獣医学部, 教授 (10325243)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
|
|---|
| Keywords | リンパ腫 / 犬 / エピジェネティック / メチル化 / アセチル化 / 抗癌剤 / 造血器腫瘍 / HAT / HDAC |
|---|
| Outline of Final Research Achievements |
To improve the treatment of the canine lymphoma patients, we focused on the epigenetic changes of the canine lymphoma cells. Our first study suggests that the detection of H3K18Ac/27Ac by the western blotting may be an appropriate method for the detection of the acetylation status in canine lymphoma cells, and if it presents, the mRNA and protein analysis of CREBBP/EP300 should be explored.
In the second study, we showed that MGMT was strongly correlated with the resistance of canine lymphoma cell lines to an anti-cancer agent, lomustine. Moreover, we show that there were two types of lymphoma cells; ones that possess the MGMT activity and show low sensitivity to lomustine, and others that do not possess the MGMT activity and show high sensitivity to lomustine. However, the canine lymphoma cell lines did not show significant correlation between the methylation status and the MGMT suppression levels.
|
